FIELD: medicine.
SUBSTANCE: claimed invention relates to granulated from liquid pharmaceutical compositions, which contain rhein or diacerein, or their salts, and pharmaceutically acceptable carrier. Compositions contain from 20 to 45 mg of rhein or diacerein. Invention also relates to methods of producing claimed compositions. Compositions by invention are bioequivalent to preparative form of diacerein in dosage 50 mg, sold under the trade name Art 50®. Compositions do not demonstrate variability in after meal condition and on an empty stomach.
EFFECT: considerable reduction of side effects, such as pulpy stool, in comparison with Art 50®.
13 cl, 37 tbl, 17 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION IN FORM OF SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPA AND ENTACAPONE, OR SALTS THEREOF | 2009 |
|
RU2519159C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING DIACEREIN | 2009 |
|
RU2542461C2 |
| MEDICINES CONTAINING DIACEREIN, AND METHODS FOR REDUCING URIC ACID LEVELS IN BLOOD WITH USING THEREOF | 2015 |
|
RU2690372C2 |
| PERORAL PHARMACEUTICAL COMPOSITIONS OF MESALAZINE | 2017 |
|
RU2744576C2 |
| NEW COMPOSITION OF LAPATINIB AS A SOLID DOSAGE FORM FOR ORAL USE AND A METHOD OF ITS MANUFACTURE | 2019 |
|
RU2821950C2 |
| METHOD OF TREATING CARDIOVASCULAR DISEASES | 2012 |
|
RU2570752C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2589842C2 |
| PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE, LEVODOPA AND CARBIDOPA WITH IMPROVED BIOAVAILABILITY | 2009 |
|
RU2485947C2 |
| PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION OF ENTACAPONE OR ITS SALTS | 2009 |
|
RU2540465C2 |
| DOSAGE FORMS FOR ORAL APPLICATION CONTAINING LICARBAZEPINE ACETATE | 2008 |
|
RU2546521C2 |
